Teitur Trophics announces successful results from Phase I clinical trial of first-in-class Parkinson’s disease peptide TT-P34

Teitur Trophics announces successful results from Phase I clinical trial of first-in-class Parkinson’s disease peptide TT-P34

Study shows TT-P34 is safe and well tolerated in healthy volunteers and patients with early-stage Parkinson’s disease (PD), with pharmacokinetics confirming robust CNS exposure Early biomarker signals are consistent with pathway modulation in the brain Teitur is planning to start a Phase II clinical trial of TT-P34 in PD in 2027 Aarhus, Denmark, September 10, […]

Teitur Trophics reports positive phase 1 data for Parkinson's peptide - European Biotechnology Magazine

Danish biotech Teitur Trophics completed its phase 1 study and said its experimental Parkinson's disease treatment TT-P34 was safe and reached the central nervous system, supporting plans to move the peptide into phase 2 testing in 2027.